Thiazolidinedione
Pioglitazone
PIOGLITAZONE
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.83 (-1.32 to -0.33) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.82 (-1.31 to -0.30) | 0.48 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.28 (-1.95 to 0.18) | 0.55 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.88 (-1.82 to 0.44) | 0.51 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Standard care or no added treatment | MD 0.19 (-1.11 to 1.33) | 0.34 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Standard care or no added treatment | MD 0.21 (-1.10 to 1.39) | 0.33 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 3.85 (2.14 to 5.52) | 0.03 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 3.94 (1.78 to 6.08) | 0.06 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.53 (-7.83 to 7.48) | 0.55 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.13 (-8.40 to 6.08) | 0.55 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.22 (0.00 to 10.64) | 0.58 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.22 (0.00 to 10.98) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.85 (0.21 to 2.93) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.95 (0.23 to 3.59) | 0.69 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.21 (0.02 to 1.27) | 0.81 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.18 (0.02 to 1.27) | 0.85 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.31 (-4.40 to -0.16) | 0.52 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.87 (-4.27 to 0.71) | 0.53 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 4.64 (-1.01 to 10.57) | 0.31 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 1.49 (-4.27 to 8.79) | 0.37 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.07 (1.02 to 4.26) | 0.20 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.98 (0.96 to 4.09) | 0.17 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.75 (0.47 to 6.08) | 0.47 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.72 (0.47 to 5.73) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.25 (0.11 to 0.51) | 0.92 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.25 (0.10 to 0.59) | 0.85 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.63 (0.29 to 1.24) | 0.83 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.69 (0.30 to 1.55) | 0.75 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.56 (0.32 to 0.92) | 0.87 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.58 (0.33 to 1.01) | 0.84 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.30 (0.11 to 0.70) | 0.89 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.34 (0.13 to 0.80) | 0.83 |
Trials
- NCT01147627Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial2010 · 416 randomized · 48 weeks
- NCT00637273A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin2008 · 514 randomized · 26 weeks
- NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes2008 · 820 randomized · 26 weeks